Dermatology

In dermatology research, the use of race and ethnicity as population descriptors has come under increasing scrutiny, with experts questioning whether these broad categories obscure more than they reveal about human health.

Healthcare professionals treating conditions such as peripheral neuropathy, wound ulcers, or radiation dermatitis now have fresh, evidence-based guidance on the use of photobiomodulation (PBM) therapy.

Radiologic imaging in high-risk cutaneous squamous cell carcinoma (cSCC) has proven more valuable than previously recognized, uncovering unexpected findings in nearly half of patients and prompting significant changes in treatment, according to a major retrospective study.

Opioid prescribing trends following outpatient surgery have seen a marked decline over the last decade, according to new U.S. claims data, signaling a nationwide shift in post-operative pain management across multiple surgical specialties.

A new systematic review and meta-analysis sheds light on the evolving understanding of body dysmorphic disorder (BDD), presented in line with recent psychiatric research updates.

Oncolytic viral therapy may offer new hope for patients with nonmelanoma skin cancers and cutaneous lymphomas, according to a new systematic review of published and ongoing research.

In a new network meta-analysis evaluating treatments for vitiligo, researchers have identified the most effective combinations of phototherapy and topical therapies, offering clinicians fresh insights into optimizing patient outcomes.

A novel combination of rhinoshave and fractional ablative CO2 laser therapy is proving to be a safe and effective approach for treating pronounced rhinophyma, offering precise contouring with minimal complications and high patient satisfaction, according to a new study.

Biologic therapies significantly reduce the risk of major adverse cardiovascular events (MACEs) in patients with psoriasis and psoriatic arthritis (PsA), offering potential heart health benefits beyond skin and joint relief.

A clinical trial has assessed whether 3D total-body photography (TBP) combined with sequential digital dermoscopy imaging (SDDI) enhances melanoma detection in high-risk patients.

A novel high-intensity, high-frequency ultrasound device has demonstrated significant effectiveness in reducing facial acne scars, according to a new clinical study.

Blood plasma, fibrinogen, and fibrin have long been explored for their role in skin tissue engineering and dermatological treatments, with promising preclinical results—but clinical adoption remains limited.

Body-focused repetitive behaviors (BFRBs), including skin-picking, hair-pulling, and nail-biting, significantly impact quality of life, yet access to effective treatments remains a challenge.

AI and machine learning (ML) are reshaping dermatopathology by improving diagnostic accuracy, enabling predictive analytics, and optimizing workflows.

Dietary recommendations for psoriasis on Instagram have been analyzed in a new study, which found that nearly all posts lack scientific credibility, with most advice coming from unqualified individuals.

A recent phase 3 open-label extension study has demonstrated that delgocitinib cream is both safe and effective for long-term management of chronic hand eczema (CHE) in adults.

Increasing diversity in research, from basic science to clinical trials, remains essential for advancing equitable healthcare outcomes.

Achieving comprehensive education in skin of colour (SoC) dermatology remains a challenge in residency programs, with significant disparities in exposure to diverse skin tones across institutions.

Patients with severe alopecia areata (AA) may experience prolonged hair regrowth even after discontinuing treatment with bempikibart, according to findings from the SIGNAL-AA phase 2a study presented at the American Academy of Dermatology (AAD) Annual Meeting.

A phase 2 clinical trial has demonstrated that a once-daily oral tyrosine kinase 2 (TYK2) inhibitor significantly improves symptoms in adults with moderate to severe plaque psoriasis, achieving high clearance rates with a safety profile comparable to placebo.

A new analysis of five clinical trials confirms that dupilumab significantly improves lichenification in patients with moderate to severe atopic dermatitis (AD) across all ages and racial backgrounds.

Artificial intelligence (AI) is becoming a key tool in skin cancer diagnosis, but patient acceptance remains a critical aspect of its implementation.

A recent study has revealed that adult survivors of childhood cancer face a significantly elevated risk of developing melanoma, underscoring the necessity for vigilant long-term monitoring and tailored preventive strategies.

A recent global retrospective cohort study has demonstrated that dupilumab, a monoclonal antibody used to treat atopic dermatitis (AD), offers a favorable cardiometabolic safety profile compared to traditional systemic agents such as methotrexate and cyclosporine.

The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Zabalafin Hydrogel, a novel therapy designed to treat mild to moderate atopic dermatitis (AD) comprehensively.

Long-term data reveal that bimekizumab, a dual IL-17A and IL-17F inhibitor, provides sustained symptom control for patients with hidradenitis suppurativa (HS).

A recent meta-analysis suggests that statin use is associated with improved survival outcomes in patients with cancer undergoing immune checkpoint inhibitor (ICI) therapy.

A recently published review examined the impact of obesity, diabetes, and smoking on surgical outcomes for patients with hidradenitis suppurativa (HS).

Recent advancements in artificial intelligence (AI) are reshaping dermatology, particularly in diagnosing skin diseases like skin cancer.

Survivors of blood or marrow transplants (BMT) face a significantly higher risk of developing cutaneous malignant neoplasms, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma, according to a recent cohort study.

The University of Pennsylvania Health System has revealed that targeted educational interventions can significantly enhance healthcare workers’ understanding and management of regulated medical waste (RMW) in a recent study.

A new retrospective study has shed light on the incidence of cutaneous pyogenic granulomas (PGs) by age, sex, and anatomical location.

Understanding why some patients with melanoma respond to immunotherapy while others do not has remained a critical challenge for precision medicine.

A recent clinical trial has shown promising results in treating severe, active vitiligo through a combination of oral medication and phototherapy, offering new hope for managing this challenging condition.

Fixed-combination topical therapies show improvements in acne within the first 4 weeks of treatment, according to new data compiled from pivotal clinical trials.

A groundbreaking clinical trial has provided valuable insights into the management of dermatoporosis, a condition characterized by chronic extracellular matrix (ECM) degradation leading to skin atrophy and fragility.

A recent large-scale study published in a dermatology journal provides important insights into the cardiovascular safety of biologic therapies for patients with psoriasis or psoriatic arthritis (PsA).

A new systematic review has shed light on the safety of beta blockers for treating PHACE syndrome, addressing concerns about stroke risk in patients with cerebrovascular and cardiovascular anomalies.

A recent study has highlighted metformin’s potential role in reducing the risk of non-melanoma skin cancers (NMSC), offering intriguing possibilities for dermatological and oncological care.

A new study reveals that patients with cutaneous lupus erythematosus (CLE) face significantly higher risks of atherosclerotic cardiovascular disease (ASCVD) compared to the general population.

A recent study has uncovered promising advancements in the fight against Stage II melanoma by introducing a novel biomarker technique, immune Förster resonance energy transfer (iFRET).

An epidemiological study has shed light on the primary risk factors driving Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer.

Patients with moderate-to-severe atopic dermatitis who did not initially meet response criteria for lebrikizumab at 16 weeks can still achieve improvements with continued therapy, according to a recent clinical trial analysis.

The VISIBLE trial sets a benchmark for diversity in psoriasis research, achieving rapid enrollment and valuable data for patients with skin of color.

The most commonly treated pediatric cosmetic conditions included hypertrophic and traumatic scars, acne, axillary and facial hyperhidrosis.

This study highlights the importance of recognizing physiologic volar melanotic macules in clinical practice, particularly in individuals with skin of color

An international expert panel of 43 dermatologists has established an expert consensus on the off-label use of low-dose oral minoxidil (LDOM) for treating hair loss.

In an effort to improve psoriasis research, the VISIBLE clinical trial has made significant strides in diversity, enrolling participants with skin of color (SoC) at an accelerated rate.

A recent cohort study involving 144,447 participants has found a crucial threshold in melanoma risk for tumors with a Breslow thickness between 0.8 and 1.0 mm.

Survivors of cutaneous melanoma (CM) face a 57% increased risk of developing second primary malignancies (SPMs) compared to the general population, according to groundbreaking research from a recent analysis of SEER database data spanning two decades.

Navigating treatment options for hidradenitis suppurativa (HS) may include consideration of clinic-based deroofing as a more effective and economical choice compared to local excision.

A recent multicenter cohort study reveals that preterm infants are more likely to develop severe forms of infantile hemangiomas (IH), raising concerns about delayed diagnosis and potential scarring risks.

A newly published review sheds light on how the digital revolution is reshaping the field of cosmetic dermatology.

A new study has revealed how the protein Rab7a enhances the activity of TPC2, a cellular channel linked to melanoma, the deadliest form of skin cancer.

A cutting-edge alternative to traditional skin creams offers a promising new approach for treating inflammatory skin diseases.

Results from the Phase III ICONIC-LEAD trial reveal that JNJ-2113 (icotrokinra, Johnson & Johnson, New Jersey), an oral peptide targeting the IL-23 receptor, demonstrated improvements in skin clearance among patients with moderate to severe plaque psoriasis.

A significant risk associated with immune checkpoint inhibitors (ICIs), a class of cancer therapies, has been identified in a new study.

A recent study has found a significant association between fine particulate air pollution (PM2.5) and eczema, highlighting a potential environmental driver of the skin condition among American adults.

New evidence highlights the potential of laser hair removal and intense pulsed light (IPL) therapy in reducing lesion count and flare-ups for patients with hidradenitis suppurativa (HS).

Wide local excision and Mohs surgery are the leading treatments for melanoma patients with positive tumor margins, according to findings presented at the American Society for Dermatologic Surgery Annual Meeting.

Nutritional and microbial strategies are emerging as pivotal in treating skin conditions such as acne, alopecia, and atopic dermatitis.

Nearly half of patients with metastatic melanoma treated with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab have survived cancer-free, underscoring the impact of immunotherapy in advanced melanoma.

A major randomized clinical trial has demonstrated that home-based narrowband UV-B phototherapy is as effective as office-based treatment for patients with plaque or guttate psoriasis.

A clinical trial has shown that dupilumab, a monoclonal antibody targeting IL-4 and IL-13, may offer benefits to patients in managing bullous pemphigoid, a rare autoimmune blistering disease.

A strong link between childhood obesity and the development of immune-mediated skin diseases has been highlighted in new research.   

Approval has been granted by the FDA for lebrikizumab-lbkz in treating moderate to severe atopic dermatitis in patients aged 12 and older.

Gaps in dermatology education have been spotlighted in preclinical medical students.

The UNCOVER-3 trial is a recent study that has demonstrated that ixekizumab, a biologic treatment for moderate-to-severe plaque psoriasis, is effective in managing psoriasis across challenging body areas including the scalp, face, palmoplantar surfaces, or nails.

Research suggests that Alcaligenes faecalis, a bacterium found in many chronic wounds, can aid in healing difficult-to-treat wounds, especially in people with diabetes.

Results from an ongoing study have demonstrated a high burden of arthritis symptoms in patients with psoriasis.

A study has explored the relationship between psoriasis and COPD to determine whether psoriasis patients are at increased risk for developing COPD.